Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Postponement of Meeting
The Food and Drug Administration (FDA) is postponing the joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Adviso...
The Food and Drug Administration (FDA) is postponing the joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee scheduled for November 18, 2022. Future meeting dates will be announced in the
Federal Register
.
FOR FURTHER INFORMATION CONTACT:
Moon Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894,
NDAC@fda.hhs.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION:
The joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs
( printed page 65071)
Advisory Committee was originally announced in the
Federal Register
of September 13, 2022 (87 FR 56071). The meeting has been postponed to allow time for FDA to review new information. Future meeting dates will be announced in the
Federal Register
.
Use this for formal legal and research references to the published document.
87 FR 65070
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Postponement of Meeting,” thefederalregister.org (October 27, 2022), https://thefederalregister.org/documents/2022-23379/joint-meeting-of-the-nonprescription-drugs-advisory-committee-and-the-obstetrics-reproductive-and-urologic-drugs-advisor.